What happened
Brain-computer interface developer Science Corporation has closed a $400m Series D, the US company announced in a blog post on Tuesday, TNW | Deep-tech reported. Backers include Y Combinator, Khosla Ventures, PLC Neurotech, Tenet Healthcare, 885 Capital and the Ackman Oxman Institute, alongside other investors. The company did not identify a lead investor and did not say what the round values it at.
The new capital is earmarked for broadening access to PRIMA, the company's retinal implant, across Europe and for groundwork ahead of a US launch. Science intends to pursue FDA approval via the Humanitarian Device Exemption, a route meant for devices serving small patient populations. Remaining funds will go to research, manufacturing and a biohybrid brain interface that relies on lab-grown neurons to connect electronics with the brain.
The raise lifts Science's total funding past $900m since its founding in 2021. It comes eight months after a $230m Series C, a round that was reported at the time to value the company at $1.5bn. Science is led by Max Hodak, a Neuralink co-founder who previously served as that company's president.
Context
PRIMA is a chip placed beneath the retina that operates together with camera glasses, aimed at people whose central vision has been lost to geographic atrophy, an advanced stage of dry age-related macular degeneration. It obtained a CE mark in July, permitting sales in 30 European countries, and Science says it is the first brain-computer interface carrying that mark to restore form vision, meaning reading letters, numbers and words.
El boletín
La semana tecnológica, en un solo correo.
Las crónicas que merecen su tiempo, cada semana. Cancele la suscripción cuando quiera.
